Danaher Corp. (DHR): Price-to-Projected Revenue Ratio

Public company logo of Danaher Corporation (DHR)

Strong pricing power in biomedicine guarantees Danaher Corp. (DHR) a steady cash flow. The projected P/S multiple confirms this correlation, where 4.20 is recorded as the baseline value. The holding's robust liquidity relies on regular sales of consumables. Meanwhile, the business maintains resilience during recessions due to its diagnostic profile, ignoring economic downturns.

Danaher - DHR Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for danaher.com (DHR)

- stock price and consensus target price:
Stock Quotes Danaher Corporation|DHR - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Danaher Corp.|DHR - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Danaher|DHR - Total Stockholders' Equity|Market Value to Book Value Ratio danaher.com|DHR - Total Business Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio Danaher Corp.|DHR - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Danaher Corporation|DHR - Company Total Debt Obligations|Debts to Book Capitalization Danaher Corp|DHR - Company Long-Term Indebtedness|Company Short-Term Debts Danaher|Quick Liquidity danaher.com
- financial results and valuation multiples details:
DHR - Company Profit|Projected Future Earnings Danaher Corp.|DHR - P/E Multiple|Forward P/E Multiple Danaher Corp.|DHR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Danaher Corporation Inc.|DHR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Danaher|DHR - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months danaher.com|DHR - Earnings per share increase in current year|Earnings growth forecast for next year Danaher Corp.
- revenue and sales details:
DHR - Company Sales|Company Projected Revenue danaher.com|DHR - Price to Sales|Price-to-Projected Revenue Ratio Danaher Corp.|DHR - Revenue Dynamics YoY (Last Twelve Months)
Comprehensive company analysis:Danaher Corp. DHR
Manufactured products of Danaher Corp.

The efficiency of the DBS system and the capital allocation expertise of Danaher Corp. (DHR) ensure high cash flow predictability. By analyzing the forward price-to-sales chart, an investor can track the daily market value of every dollar of expected revenue, which eliminates the lags between quarterly reports. This indicator allows for the comparison of current quotes with projected sales, identifying risks of asset overvaluation during periods of volatility.

Competitor analysis for Danaher Corp.

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Becton Dickinson & Company BDX|STE - Price-to-Projected Revenue Ratio|West Pharmaceutical Services (WST) - Forward Price-to-Revenue Multiple|BAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Masimo|STVN (stevanatogroup.com) - Forward P/S Multiple|Market Cap to Projected Revenue TFX (Teleflex Incorporated)|Price-to-Projected Revenue Ratio Merit Medical (MMSI)|Envista - Market Cap to Projected Revenue|ICU Medical, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XRAY (Dentsply Sirona Inc)|LMAT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio AtriCure Corp ATRC|staar.com (STAA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ChromaDex Corporation|ZIMV (ZimVie Inc) - Forward P/S Multiple|Market Cap to Projected Revenue ANGO (AngioDynamics)|Price-to-Projected Revenue Ratio Cerus Corp (CERS)|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com